Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
A Phase 3 trial investigating Boehringer Ingelheim’s nerandomilast in idiopathic pulmonary fibrosis hit its primary endpoint, ...
GlobalData on MSN11d
Boehringer Ingelheim reports positive results from trial of HER2 lung cancer drugThe trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results GlobeNewswire September 05, 2024 Ingelheim, Germany and Basel ...
INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address ...
INGELHEIM, Germany, September 03, 2024 – Boehringer Ingelheim today said it has acquired Saiba Animal Health AG, a company focused on the development of novel therapeutic medicines to address chronic ...
Boehringer Ingelheim, a biopharmaceutical company involved in both human and animal health, has acquired Saiba Animal Health (SAH), a company that develops therapeutic vaccines, targeting unmet needs ...
At the IASLC 2024 World Conference on Lung Cancer (WCLC) Boehringer Ingelheim will present encouraging data from across its oncology pipeline, illustrating its aspiration to transform the lives of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback